Researchers still need better data to tell apart Alzheimer's, Lewy body disease, vascular injury and mixed dementias in adults with memory concerns. The National Institute on Aging (NIA) focus in 2026 points to fragmented large datasets and missing co-pathology measures as the key gaps.
A dementia subtype means the specific brain disease driving memory and thinking changes. Adults with non-Alzheimer or mixed disorders face the largest uncertainty. Better subtype data would support more accurate diagnosis, trial matching and care planning.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why mixed causes get missed
- Which subtypes need better data?
- What markers must be measured next?
- Why big datasets are not enough yet
- What to ask at your evaluation
Why mixed causes get missed
Frontiers in Aging Neuroscience analyzed 1,920 National Alzheimer's Coordinating Center participants followed from 2005 to 2019. Over 61% with autopsy-confirmed Alzheimer's plus Lewy body disease had received a clinical diagnosis of Alzheimer's alone, in the Frontiers in Aging Neuroscience analysis.
Lewy body protein and vascular injury can occur alongside Alzheimer changes. A routine visit may record only one cause. Autopsy later can show more than one disease was present.
Which subtypes need better data?
The University of Washington ADRC describes the NIA-partnered ADRD Summit 2025 priorities. Priorities included frontotemporal degeneration, Lewy body dementia, vascular contributions and multiple-etiology dementias, plus health equity, in the University of Washington ADRC event page. Approved recommendations became National Plan milestones for adults with non-Alzheimer or mixed disorders.
This matters when symptoms do not fit one pattern. Behavior or language changes, movement or sleep changes, prior stroke or small-vessel disease, or more than one process may signal a listed subtype. Those adults need studies built around their pattern, not only Alzheimer studies.
What markers must be measured next?
A February 2026 review in PMC/Frontiers in Dementia describes the 2024 NIA-Alzheimer's Association biological definition. It expands AT(N) to AT1T2NISV, in the PMC/Frontiers in Dementia review. S means alpha-synuclein, the Lewy body protein, and V means vascular injury.
Researchers still must measure those co-pathology markers alongside Alzheimer biomarkers. Without S and V data, mixed disease stays hidden. With them, subtype answers become more precise.
Why big datasets are not enough yet
An ICPSR preview says NIA's Aug. 19, 2026 Big Data to Big Insights workshop addresses fast-growing aging and AD/ADRD data resources. It frames fragmentation and methods gaps as limits on subtype answers, in the ICPSR workshop preview.
Data often sit in separate clinics, registries and labs with different tests and terms. Linking clinical, biomarker and autopsy measures takes common definitions and stronger methods. Until then, large data holdings cannot reliably separate subtypes.
What to ask at your evaluation
Ask what evidence supports each part of the diagnosis. The same workshop message encourages patients to ask what data and biomarker tests back their diagnosis.
Bring prior scans, test results and a symptom timeline to that visit. Ask which result supports Alzheimer changes, Lewy body disease or vascular injury.
- Ask which subtype pattern best fits the results so far
- Ask which Alzheimer, alpha-synuclein and vascular markers were tested
- Ask what remains uncertain and what follow-up would clarify it
- Ask whether trial eligibility depends on subtype or co-pathology testing
You Might Also Like
- Privacy and Data Access Gaps in 2026 Dementia Research: What Researchers Still Need to Learn for Adults With Memory Concerns
- WHO’s Second Dementia Risk-Reduction Guideline in 2026: How Adults Over 65 Can Avoid Overreading the Headline
- The WHO 45% Modifiable Dementia Risk Estimate in 2026: How Adults Over 65 Can Avoid Overreading the Headline
